Veracuity was conceived out of a recognition that the practice of pharmacovigilance is performed suboptimally. That is because it relies entirely on a voluntary reporting system – one in which consumers and healthcare professionals must devote considerable energy if they were so inclined to notify somebody about a side effect they attribute to a bio-pharmaceutical product. Adverse event reporting is infrequent and cumbersome because stakeholders are only vaguely aware of their responsibility and the current system is neither easy nor fast to use. Nor does it provide reporters with any immediate helpful feedback. With only a very small percentage of adverse drug events ever reaching the attention of manufacturers or regulators, it is easy to conclude that the medical community and the public may be wholly unaware of tremendous risks and liabilities that may be attributed to drug products.
This workshop allows participation in insightful conversation on the future of our industry.
Program: Fishbein, J: Introduction and closing remarks.
Barrett, CP: Implementation of Post-marketing Risk Management Commitment.
Laugel, I: The future of pharmacovigilance with the use of artificial intelligence sounds good.
Marschler, M: The use of pharmacogenomic methodologies in the pharmacovigilance evaluation of medicinal products.